Chairman
AMICUS THERAPEUTICS, INC.
CEO
AMICUS THERAPEUTICS, INC.
Board Member
AMICUS THERAPEUTICS, INC.
Equibles does not estimate personal net worth.
John Crowley is recorded as Chairman, CEO and Board Member at AMICUS THERAPEUTICS, INC. and CFO at Centessa Pharmaceuticals plc (CNTA). The newest filing on record that lists John Crowley as CFO at Centessa Pharmaceuticals plc (CNTA) is dated April 29, 2026. Centessa Pharmaceuticals plc reported in an 8-K filed June 24, 2026 that John Crowley was terminated as Executive Officer, effective June 24, 2026. Centessa Pharmaceuticals plc reported in an 8-K filed June 10, 2024 that John Crowley was appointed Chief Financial Officer, effective June 10, 2024. The proxy statement of Centessa Pharmaceuticals plc reports total compensation of $3,842,835 for John Crowley in fiscal 2025, including a base salary of $534,625. Disclosed compensation is on record for 3 fiscal years. John Crowley has spoken on 7 earnings calls across 1 company, most recently for AMICUS THERAPEUTICS, INC. on May 9, 2022. AMICUS THERAPEUTICS, INC. is classified in the Biotechnology industry within the Healthcare sector. Centessa Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Centessa Pharmaceuticals plc includes Mario Alberto Accardi (CEO and Board Member), Francesco De Rubertis (Chairman), Thomas Templeman (CTO) and 7 others.
“Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.”
“On June 10, 2024, Centessa Pharmaceuticals plc (the "Company") announced the appointment of John Crowley as Chief Financial Officer, which was approved by the Board of Directors of the Company on June 5, 2024, effective June 10, 2024 (the "Start Date").”
“Thank you, Andrew, and welcome everyone to our first quarter 2022 results conference call.”
“I am pleased to highlight the progress that we’ve made at Amicus throughout 2021 and now into the start of 2022, a reflection of the broad execution across our business.”
“And welcome to our third quarter 2021 results conference call. I am pleased to report that the third quarter reflected broad execution across our business as we remain on track to achieve our key strategic priorities for the year.”
“Thank you, Andrew and welcome everyone to our second quarter 2021 results conference call. Before we begin, I just want to note yesterday the sudden death of Dr. Tachi Yamada.”
“Yesterday, February 28th marked the 14th Annual World Rare Disease day. The goal of this day is to raise awareness with policymakers and the public of rare diseases and their impact on the lives of the millions of people and their families living with any one of the more than 7,000 rare diseases.”
AMICUS THERAPEUTICS, INC.
Chairman
Source not stated
AMICUS THERAPEUTICS, INC.
CEO
Proxy statement
AMICUS THERAPEUTICS, INC.
Board Member
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
AMICUS THERAPEUTICS, INC.
Biotechnology · Healthcare
Chairman, CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Centessa Pharmaceuticals plc (CNTA) | Chief Financial Officer | $534,625 | $3,842,835 |
| 2024 | Centessa Pharmaceuticals plc (CNTA) | Chief Financial Officer | $295,313 | $4,120,748 |
| 2023 | Centessa Pharmaceuticals plc (CNTA) | Chief Financial Officer | — | — |
AMICUS THERAPEUTICS, INC. Q1 FY2022 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q4 FY2021 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q3 FY2021 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q2 FY2021 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q4 FY2020 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q3 FY2020 Earnings Call
AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. Q1 FY2020 Earnings Call
AMICUS THERAPEUTICS, INC.
